Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 8,272 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Sickle Cell Disease
Interventions: Alemtuzumab, Fludarabine, Melphalan, Stem Cells; Drug · Procedure
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 2 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 544 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Healthy Lifestyle, Home Environment Related Disease, Child Behavior, Cognitive Change, Child Obesity, Parenting, Parents, Parent-Child Relations
Interventions: Healthy HomeStyles, Eat Healthy Be Active; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 110 Years
Enrollment: 247 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Chronic Obstructive Pulmonary Disease, HIV, Emphysema
Interventions: blood draw, questionnaires, Lung function testing, Six-Minute walk test, Quantitative CT scans, Nasal secretion and cell collection, Echocardiogram; Procedure · Radiation
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pneumococcal Infection
Interventions: 23-valent pneumococcal polysaccharide vaccine, 13-valent pneumococcal conjugate vaccine; Biological
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 50 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Pain, Postoperative
Interventions: Indomethacin Capsules low dose, Indomethacin Capsules high dose; Drug
Lead sponsor: Iroko Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 5
States / cities: Sheffield, Alabama • Aurora, Colorado • Coral Gables, Florida + 2 more

Conditions: Primary Immunodeficiency Disorders
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 90 Years
Enrollment: 1,190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2040
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Multiple Sclerosis
Interventions: MRI Scan; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression
Interventions: MoodHelper Internet program for Depression Self-Help; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 14 Years to 24 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Community-acquired Bacterial Pneumonia
Interventions: Solithromycin, Standard of Care; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 2 Months to 17 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more

Conditions: Intracerebral Hemorrhage
Interventions: Not listed
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Chicago, Illinois • Louisville, Kentucky • Baltimore, Maryland + 4 more

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: BNT162b2, BNT162b2.B.1.351; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 1,574 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 17
States / cities: Oakland, California • Milford, Connecticut • Hialeah, Florida + 13 more

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections, Influenza
Interventions: Quadrivalent VLP Vaccine, Placebo; Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 10,160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 29
States / cities: Mobile, Alabama • Anaheim, California • Milford, Connecticut + 23 more

Conditions: Fractures, Bone
Interventions: Blood draws to assess RNA expression levels; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Sacramento, California • Bloomington, Indiana • Columbia, Missouri + 4 more

Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours); Drug
Lead sponsor: Innoviva Specialty Therapeutics; Industry
Eligibility: 1 Day to 18 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • San Diego, California • Greenville, North Carolina + 1 more

Conditions: Brain Concussion, Mild Traumatic Brain Injury, Motor Disorders, Cognitive Impairment
Interventions: tDCS in Youth with mild traumatic brain injury; Device
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 10 Years to 15 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Cardiovascular Imaging Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Iron Deficiency, Anemia
Interventions: Fer-in-Sol, control; Dietary Supplement · Other
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 4 Weeks to 9 Months
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 7 Years to 12 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 32
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 24 more

Conditions: Chronic Obstructive Pulmonary Disease, COPD
Interventions: Tiotropium, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hematologic Disorders, Hemoglobinopathies, Immunodeficiencies
Interventions: Busulfan, Fludarabine, Total body irradiation, Stem cell transplant, Keppra; Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Acute Myeloid Leukemia
Interventions: combination therapy using decitabine and midostaurin; Drug
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Reading Disability, Dyslexia
Interventions: Not listed
Lead sponsor: Scripps Health; Other
Eligibility: 7 Years to 13 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Appetite
Interventions: Egg Breakfast, Bagel Breakfast; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 4 Years to 17 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Search by objective public record fields.

Stem Cell Transplantation for Sickle Cell Anemia

Feasibility of Cocooning Immunization Strategy With Influenza Vaccine

HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity in SNAP-Education

Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes

Pneumonia Vaccine in Aging HIV Positive Individuals

Study of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age

The Mechanistic Biology of Primary Immunodeficiency Disorders

pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress

Study of a Self-Help Depression Skills Program for College-Aged Youth

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

ROSE-Longitudinal Assessment With Neuroimaging

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

855303-RNA Biomarker Validation

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

Neuromodulation and Neuroimaging in Older Children With Mild Traumatic Brain Injury

Direct Comparison of 2D Cardiac PET With 3D Cardiac PET

Prevention of Iron Deficiency in Breastfed Infants

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia

Eye Movements and Reading Disabilities

The Satiating Effect of Eggs in Children